

COUNTY OF SAN LUIS OBISPO HEALTH AGENCY PUBLIC HEALTH DEPARTMENT Michael Hill Health Agency Director Penny Borenstein, MD, MPH Health Officer/Public Health Director

## **PROVIDER HEALTH ADVISORY**

**Date:** August 23, 2021 **Contact**: Rick Rosen, MD, MPH (805)781-5500, frosen@co.slo.ca.us

## Urgent Appeal to Administer Monoclonal Antibody Therapy for COVID-19 in the County of San Luis Obispo

The County of San Luis Obispo Public Health Department has a supply of REGEN-COV™ (casirivmab and imdevimab) that is available to all medical providers in San Luis Obispo County at no cost to the provider.

The FDA has issued an Emergency Use Authorization (EUA) to permit the use of REGEN-COV for both the treatment of mild to moderate COVID-19 and for post-exposure prophylaxis against COVID-19 in individuals who are at high risk for progression to severe disease. In addition, the current EUA allows for the administration of REGEN-COV via either intravenous infusion or **subcutaneous injection**.

Results from clinical trials indicate that REGEN-COV reduces the risk of COVID-19 related hospitalization or all-cause death by 70% in individuals with mild to moderate COVID-19 and <u>at least one risk factor for progression to severe disease</u>. With respect to post-exposure prophylaxis, there is an 81% risk reduction in the development of COVID-19 with REGEN-COV treatment versus placebo.

## Currently, hospitals in SLO County are experiencing a significant surge of severely ill patients with COVID-19. It is critical that providers take a more active role in providing this highly effective medication to both improve patient outcomes and to protect local healthcare system capacity.

If you are interested in offering REGEN-COV to your patients, please contact Deputy Health Officer Rick Rosen, MD, MPH immediately via email at <u>frosen@co.slo.ca.us</u>, and we will help get you started.

## For More Information

• <u>Fact Sheet for Health Care Providers Emergency Use Authorization of REGEN-COV</u> (casirivimab and imdevimab) (fda.gov)